Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors

NCT00404508 is registered in ClinicalTrials.gov with National Institute of Cancerología as lead sponsor.

NCT NCT00404508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00404508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors
Lead sponsor
National Institute of Cancerología
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
October 31, 2006
Enrollment
15
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory solid tumors